|
Samaritan
Presents Favorable Caprospinol Data At Alzheimer's Drug
Development Summit November 30
Tuesday November 27, 9:23 am
ET
Return
to Homepage | See All News
- Conference
Showcases the Latest Disease Modifying Therapies and
Pre-Symptomatic Approaches for Alzheimer's Drug Development
- Dr.
Lecanu to Present Favorable Caprospinol Data Showing
the Clearing
of A-beta Plaque From Brain Leads to Recovery of Memory
Function in
Animals
Samaritan
Pharmaceuticals, Inc. (OTC BB:SPHC.OB) is pleased to announce
that Laurent Lecanu, Ph.D., Pharm.D., will present data
for Samaritan's promising Alzheimer's drug Caprospinol
(SP-233) at the Alzheimer's Drug Development Summit
in Arlington, VA on Friday, November 30th at 9:45a.m./ET.
Dr. Lecanu will present Caprospinol as the first drug
to demonstrate in animals that there is a correlation
between clearing beta-amyloid from the brain and the
recovery of memory function. Dr. Lecanu's presentation
is entitled "Caprospinol Improves Brain Histopathology
and Recovers Memory Function in a Rat Model of Alzheimer's
Disease.''
|
| Dr.
Lecanu is an associate professor of the Department
of Medicine at the Research Institute of the McGill
University Health Centre and through a Samaritan
research collaboration with McGill University heads
Samaritan's research efforts. |
|
For
more information about the conference, please visit:
http://www.cbinet.com/show_conference.cfm?confCode=PC07088&field=summary
In an
in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals,
Inc. has confirmed Caprospinol's (SP-233) efficacy in its
ability to dramatically decrease beta amyloid plaque in the
brain, accompanied by a complete recovery of memory back to
baseline (p=0.002), as shown in a Morris water maze task.
This study confirms previously reported in vitro data and
suggests Caprospinol may not only slow the progress of Alzheimer's,
but may also reverse plaque-related brain injuries associated
with the disease. The rats tested with the company's proprietary
Alzheimer's rat model took on features similar to the crippling
signs of dementia seen in human patients suffering from Alzheimer's;
by treating the rats with Caprospinol, the rat's brain cells
regained complete memory.
Dr. Lecanu
is an associate professor of the Department of Medicine at
the Research Institute of the McGill University Health Centre
and through a Samaritan research collaboration with McGill
University heads Samaritan's research efforts.
Samaritan
Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's
Cures...''
Samaritan
Pharmaceuticals is an entrepreneurial biopharmaceutical company
that concentrates its efforts toward commercializing new innovative
therapeutic products. Samaritan has partnered its Phase II
infectious disease drug SP-01A, an oral HIV viral-entry inhibitor,
to Pharmaplaz, Ireland. Additionally, its Alzheimer's drug
Caprospinol, with the potential to restore memory loss in
Alzheimer's disease patients, has been issued an IND by the
FDA. Samaritan has several drugs in nonclinical studies preparing
for IND development; it is evaluating the use of SP-1000 for
hypercholesterolemia patients and the use of SP-10T1 as an
``oral treatment'' for Hepatitis-C. In addition, Samaritan
has acquired the marketing and sales rights to sell eleven
revenue-generating products in various Eastern European countries.
Disclaimer
The
company disclaims any information created by an outside
party and endorses only information communicated by its
press releases, filings, and Website. This news release
contains forward-looking statements that reflect management's
current beliefs about the potential for its drug candidates,
science, and technology. However, as with any biopharmaceutical
under development, there are significant risks and uncertainties
in the process of development and regulatory review. There
are no guarantees that products will prove to be commercially
successful. For additional information about the factors
that affect the company's business, please read the company's
latest Form 10-Q filed November 19, 2007. The company
undertakes no duty to update forward-looking statements.
Website:
http://www.samaritanpharma.com.
Please register so we can notify you of upcoming conference
calls, news and events.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
